Get the Stockscreener App
1.105
8.68%
-0.105
Exicure Inc stock is traded at $1.105, with a volume of 9,928.
It is down -8.68% in the last 24 hours and down -15.65% over the past month.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
9,928
Relative Volume:
0.22
Market Cap:
$7.23M
Revenue:
$500.00K
Net Income/Loss:
$-9.78M
P/E Ratio:
-0.7166
EPS:
-1.5419
Net Cash Flow:
$-8.10M
1W Performance:
+10.50%
1M Performance:
-15.65%
6M Performance:
-72.07%
1Y Performance:
-78.29%
1-Day Range:
$1.105
$1.24
1-Week Range:
$0.936
$1.26
52-Week Range:
$0.936
$9.4799
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XCUR
Exicure Inc
|
1.105 | 7.23M | 500.00K | -9.78M | -8.10M | -1.5419 |
VRTX
Vertex Pharmaceuticals Inc
|
508.89 | 128.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.19 | 95.10B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.60 | 82.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.78 | 53.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure Gets Nasdaq Extension as Delisting Risk Persists - MyChesCo
Cyngn Inc.Common stock (NQ: CYN - The Chronicle-Journal
Exicure Inc (NASDAQ: XCUR) Share Price, XCUR Stock News, XCUR Share Price & Updates - kalkine.ca
Nasdaq gives Exicure until Dec. 2 to show it has $2.5 million left after debts - Stock Titan
Free cash flow of Exicure, Inc. – HAM:2H0 - TradingView
Cash flow from investing activities of Exicure, Inc. – HAM:2H0 - TradingView
Total common shares outstanding of Exicure, Inc. – HAM:2H0 - TradingView
Return on assets % of Exicure, Inc. – HAM:2H0 - TradingView
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Barchart.com
Exicure (XCUR) Watch: Falls 11.54% to $1.15 in the Latest Session; Range View: Support at $1.09 and Resistance at $1.21 Frame the RangeRounding Top - vinanet.vn
Exicure (XCUR) Price: Declines 11.54% to $1.15 in the Latest Reading; Range View: Support at $1.09 and Resistance at $1.21 Frame the Range for the Current SessionEqual Weight ETF - vinanet.vn
Exicure (XCUR) Quarterly Figures: EPS Comes in Below Forecast for This Review; Share Response: The Stock Ends Down 10.34% for the Current SessionGuidance Update - vinanet.vn
Exicure Stock Price Forecast. Should You Buy XCUR? - StockInvest.us
EXICURE, INC. Q2 2026: Revenue $0 Net income $(1.12M) — 10-Q Summary - TradingView
Exicure Deadline Alert - TMX Newsfile
Exicure Update - TMX Newsfile
Exicure Inc (XCUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exicure Inc (XCUR) Stock News Today - TradingKey
XCUR Q2 2022 Earnings: Wider-than-Expected Loss Weighs on SharesCFO Commentary Report - vinanet.vn
Trading Systems Reacting to (XCUR) Volatility - Stock Traders Daily
Exicure Shareholder Alert - TMX Newsfile
XCUR Looks 231.6% Overvalued on GF Value™ - GuruFocus
Exicure to issue shares to settle $1M clinical milestone payment - Investing.com
Exicure to issue shares to settle $1M clinical milestone payment By Investing.com - Investing.com Nigeria
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - The Manila Times
Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics - Quiver Quantitative
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Yahoo Finance Singapore
XCUR Q2 2022 Earnings: EPS Misses by 35.6% as No Revenue ReportedDividend Cut Risk - vinanet.vn
Exicure Inc. (XCUR) Rises 4.46% to $1.64 as Shares Approach Key Resistance LevelETF Creation Redemption - vinanet.vn
Exicure Shareholder Alert - TMX Newsfile
Exicure Inc (XCUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exicure Inc (XCUR) Cash Flow - TradingKey
Exicure Inc (XCUR) Institutional Confidence - TradingKey
Exicure Inc (XCUR) Balance Sheet - TradingKey
Exicure Inc (XCUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exicure Inc (XCUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exicure Inc (XCUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XCUR|Exicure Inc|Price:1.330|Chg%:-0.180 - TradingKey
XCUR|Exicure Inc|Price:1.750|Chg%:-0.010 - TradingKey
XCUR|Exicure Inc|Price:1.760|Chg%:+0.050 - TradingKey
XCUR Q2 2022 Earnings: EPS Misses Estimates Amid Development ChallengesGuidance Revision Trend - vinanet.vn
Exicure Inc (XCUR) Income Statement - TradingKey
Exicure, Inc. Revenue Breakdown – NASDAQ:XCUR - TradingView
Exicure Inc (XCUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XCUR stock trades on limited evidence as Exicure waits for filings - Ad-hoc-news.de
XCUR|Exicure Inc|Price:1.700|Chg%:-0.010 - TradingKey
XCUR Q2 2022 Earnings: EPS Misses Estimates, Stock Declines as Pre-Revenue Biotech Faces ChallengesOperating Margin Analysis - vinanet.vn
Form 4 Exicure Inc For: 17 July By Investing.com - Investing.com Nigeria
Exicure Inc. (XCUR) Q2 2022 Earnings: EPS Misses Estimates Significantly, Stock Rises 3.7%Earnings Decline Risk - vinanet.vn
Form 13D/A EXICURE For: 17 July By Investing.com - Investing.com Nigeria
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exicure Inc Stock (XCUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Exicure HiTron Inc. | 10% Owner |
Jan 16 '26 |
Sale |
4.50 |
734,747 |
3,306,362 |
1,857,314 |
| Exicure HiTron Inc. | 10% Owner |
Jan 07 '26 |
Sale |
4.50 |
741,272 |
3,335,724 |
2,592,061 |
| SANGSANGIN INVESTMENT & SECURI | 10% Owner |
Dec 08 '25 |
Sale |
8.71 |
433,332 |
3,774,322 |
0 |
3.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):